UNSPSC 51111778: Alemtuzumab

Drug prescribed and approved by the U.S. Food and Drug Administration for the HIV infection treatment in adults and 6-year children. It is always used in combination with other drugs against the HIV. Atazanavir is a type of drug against the HIV protease inhibitor (PI). It works by blocking the protease, an enzyme produced by the HIV. This prevents HIV multiplication and reduces the virus concentration in blood.

UNSPSC 51111778 Alemtuzumab is a Commodity code for a specific monoclonal antibody immunosuppressant pharmaceutical, but recent state and local procurement activity tagged under this code does not reflect purchases of alemtuzumab itself. Instead, the recorded opportunities show state and local health agencies procuring other pharmaceutical products — broad-spectrum antibiotics, opioid-reversal medications, and drug deactivation systems — through piggyback contracts and competitive bidding processes. The issuing bodies are state health departments and county health authorities seeking to stock emergency and community health supplies at fixed annual volumes with multi-year contract terms and renewal options.

The recorded activity spans Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse cooperative purchasing vehicle to Chartwell Rx LLC on August 28, 2026, for supply of Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets over three years; Seminole County, Florida issued an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the county community health building, under a two-year initial term with one-year renewal option. The mismatch between the code's name and the actual scope of recent opportunities suggests that state and local procurement systems may be applying this code imprecisely to general pharmaceutical and medical supply purchases rather than to alemtuzumab specifically. Firms pursuing this code should verify whether their products align with the broader pharmaceutical supply categories state and local agencies are actually buying.